Author:
Lohse Ansgar W.,Mössner Joachim
Publisher
Springer Berlin Heidelberg
Reference73 articles.
1. Arzneimittelkommission der deutschen Ärzteschaft (2009) Arzneiverordnungen. Empfehlungen zur rationalen Pharmakotherapie, 22. Aufl. Medizinische Medien Informations GmbH, Neu-Isenburg, S 823–835
2. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP (2010) Rifaximin treatment in hepatic encephalopathy. N Engl J Med 362:1071–1081
3. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, VIGOR Study Group (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343:1520–1528
4. Bour B, Staub JL, Chousterman M, Labayle D, Nalet B, Nouel O, Pariente A, Tocque E, Bonnot-Marlier S (2005) Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment. Aliment Pharmacol Ther 21:805–812
5. Bouras EP, Scolapio JS (2004) Gastric motility disorders: management that optimizes nutritional status. J Clin Gastroenterol 38:549–557